US 11,738,097 B2
Curcuminoid chemotherapeutic drug carrier composition
B. Rabindran Jermy, Dammam (SA); and Vijaya Ravinayagam, Dammam (SA)
Assigned to Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed by Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed on Oct. 5, 2022, as Appl. No. 17/938,150.
Application 17/938,150 is a continuation of application No. 16/055,221, filed on Aug. 6, 2018, granted, now 11,471,542.
Prior Publication US 2023/0068832 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 49/04 (2006.01); A61K 49/18 (2006.01); A61K 49/08 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61K 31/12 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 49/0428 (2013.01) [A61K 31/12 (2013.01); A61K 47/6803 (2017.08); A61K 47/6883 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 49/08 (2013.01); A61K 49/1878 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A chemotherapeutic drug carrier composition, comprising:
a platform of nanoporous structured silica in the form of a mesocellular foam superparamagnetic iron oxide nanoparticles (“SPIONS”) in an amount in a range of from 5 wt % to 20 wt % based on total weight of the composition, and
a curcuminoid loaded in a range of from 50 to 70 wt. %,
wherein the SPIONs have an average particle size in a range of from 13 to 58 nm,
wherein the platform loaded with the SPIONs has a BET surface area in a range of from 140 to 951 m2/g,
wherein the SPIONs comprise Fe2O3 or a mixture of NiFe2O4, CuFe2O4, MnFe2O4, or CoFe2O4, and
wherein the composition has a non-burst release profile with a cumulative curcuminoid release, in phosphate buffered saline at pH 5 and 37° C. over 3 hours, in a range of from 21.3 to 53.2 wt. %, relative to total curcuminoid content in the composition.